{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:31:37Z","timestamp":1760236297567,"version":"build-2065373602"},"reference-count":60,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T00:00:00Z","timestamp":1636416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Antibiotic efficacy determination in clinical trials often relies on non-inferiority designs because they afford smaller study sample sizes. These efficacy studies tend to exclude patients within specific populations or include too few patients to discern potential differences in their clinical outcomes. As a result, dosing guidance in patients with abnormal liver and kidney function, age across the lifespan, and other specific populations relies on drug exposure-matching. The underlying assumption for exposure-matching is that the disease course and the response to the antibiotic are similar in patients with and without the specific condition. While this may not be the case, clinical efficacy studies are underpowered to ensure this is true. The current paper provides an integrative review of the current approach to dose selection in specific populations. We review existing clinical trial endpoints that could be measured on a more continuous rather than a discrete scale to better inform exposure\u2013response relationships. The inclusion of newer systemic biomarkers of efficacy can help overcome the current limitations. We use a modeling and simulation exercise to illustrate how an efficacy biomarker can inform dose selection better. Studies that inform response-matching rather than exposure-matching only are needed to improve dose selection in specific populations.<\/jats:p>","DOI":"10.3390\/antibiotics10111368","type":"journal-article","created":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T10:44:58Z","timestamp":1636454698000},"page":"1368","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Translation of Pharmacodynamic Biomarkers of Antibiotic Efficacy in Specific Populations to Optimize Doses"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7119-5034","authenticated-orcid":false,"given":"Manjunath P.","family":"Pai","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Rm 2568, 428 Church St., Ann Arbor, MI 48109, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5403-4730","authenticated-orcid":false,"given":"Ryan L.","family":"Crass","sequence":"additional","affiliation":[{"name":"Ann Arbor Pharmacometrics Group, Ann Arbor, MI 48108, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Hoffman, P.S. (2020). Antibacterial Discovery: 21st Century Challenges. Antibiotics, 9.","DOI":"10.3390\/antibiotics9050213"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): A randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/0895-4356(89)90007-3","article-title":"Sample size requirements for prospective studies, with examples for coronary heart disease","volume":"42","author":"Phillips","year":"1989","journal-title":"J. Clin. Epidemiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/infdis\/jix211","article-title":"White Paper: Developing Antimicrobial Drugs for Resistant Pathogens, Narrow-Spectrum Indications, and Unmet Needs","volume":"216","author":"Boucher","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S1473-3099(12)70293-1","article-title":"A comprehensive regulatory framework to address the unmet need for new antibacterial treatments","volume":"13","author":"Rex","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S559","DOI":"10.1093\/cid\/ciz829","article-title":"Pathogen-focused Clinical Development to Address Unmet Medical Need: Cefiderocol Targeting Carbapenem Resistance","volume":"69","author":"Echols","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3810\/pgm.2011.09.2475","article-title":"Key concepts of clinical trials: A narrative review","volume":"123","author":"Umscheid","year":"2011","journal-title":"Postgrad. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/cpt.1363","article-title":"Model-Informed Drug Development: Current US Regulatory Practice and Future Considerations","volume":"105","author":"Wang","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3109\/10601333.2015.1001900","article-title":"Special population considerations and regulatory affairs for clinical research","volume":"32","author":"Grimsrud","year":"2015","journal-title":"Clin. Res. Regul. Aff."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/jcph.744","article-title":"Exposure Matching for Extrapolation of Efficacy in Pediatric Drug Development","volume":"56","author":"Mulugeta","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/phar.2184","article-title":"Suboptimal Clinical Response Rates with Newer Antibiotics among Patients with Moderate Renal Impairment: Review of the Literature and Potential Pharmacokinetic and Pharmacodynamic Considerations for Observed Findings","volume":"38","author":"Bidell","year":"2018","journal-title":"Pharmacotherapy"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1093\/cid\/ciy790","article-title":"Renal Dosing of Antibiotics: Are We Jumping the Gun?","volume":"68","author":"Crass","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/jcph.1314","article-title":"Estimating Renal Function in Drug Development: Time to Take the Fork in the Road","volume":"59","author":"Crass","year":"2019","journal-title":"J. Clin. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"510","DOI":"10.2337\/diacare.26.2.510","article-title":"Quantifying the risk of infectious diseases for people with diabetes","volume":"26","author":"Shah","year":"2003","journal-title":"Diabetes Care"},{"key":"ref_15","first-page":"133","article-title":"The Best Pharmaceuticals for Children Act of 2002: The rise of the voluntary incentive structure and congressional refusal to require pediatric testing","volume":"40","author":"Breslow","year":"2003","journal-title":"Harv. J. Legis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1001\/jama.290.7.905","article-title":"Pediatric drug labeling: Improving the safety and efficacy of pediatric therapies","volume":"290","author":"Roberts","year":"2003","journal-title":"JAMA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e512","DOI":"10.1542\/peds.2013-2987","article-title":"Impact of pediatric exclusivity on drug labeling and demonstrations of efficacy","volume":"134","author":"Wharton","year":"2014","journal-title":"Pediatrics"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/j.clinthera.2016.06.003","article-title":"Exposure Matching of Pediatric Anti-infective Drugs: Review of Drugs Submitted to the Food and Drug Administration for Pediatric Approval","volume":"38","author":"Zimmerman","year":"2016","journal-title":"Clin. Ther."},{"key":"ref_19","first-page":"56","article-title":"Inclusion of special populations in clinical research: Important considerations and guidelines","volume":"4","author":"Winter","year":"2018","journal-title":"J. Clin. Transl. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.ejps.2017.05.022","article-title":"Evidence-based drug treatment for special patient populations through model-based approaches","volume":"109","author":"Krekels","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/cts.13061","article-title":"Design and conduct considerations for studies in patients with impaired renal function","volume":"14","author":"Ravenstijn","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e01381-16","DOI":"10.1128\/AAC.01381-16","article-title":"Pharmacokinetic\/Pharmacodynamic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, for Dose Adjustment Based on Renal Function","volume":"61","author":"Katsube","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_23","unstructured":"CDER (2013). Guidance for Industry Acute Bacterial Skin and Skin Structure Infections: Developing Drugs for Treatment, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER)."},{"key":"ref_24","unstructured":"CDER (2018). Complicated Urinary Tract Infections: Developing Drugs for Treatment Guidance for Industry, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER)."},{"key":"ref_25","unstructured":"CDER (2020). Community-Acquired Bacterial Pneumonia: Developing Drugs for Treatment Guidance for Industry, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER)."},{"key":"ref_26","unstructured":"CDER (2020). Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia: Developing Drugs for Treatment Guidance for Industry, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER)."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/cid\/ciw191","article-title":"Handling Time-dependent Variables: Antibiotics and Antibiotic Resistance","volume":"62","author":"Frencken","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00134-003-2018-2","article-title":"Clinical pulmonary infection score for ventilator-associated pneumonia: Accuracy and inter-observer variability","volume":"30","author":"Schurink","year":"2004","journal-title":"Intensive Care Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e1507","DOI":"10.1093\/cid\/ciaa974","article-title":"Ceftobiprole Compared with Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Results of a Phase 3, Randomized, Double-blind Trial (TARGET)","volume":"73","author":"Overcash","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1056\/NEJMoa1800170","article-title":"Omadacycline for Acute Bacterial Skin and Skin-Structure Infections","volume":"380","author":"Green","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/cid\/ciy165","article-title":"A Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin With Vancomycin Plus Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Multinational, Double-Blind, Randomized Study","volume":"67","author":"McManus","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1093\/cid\/cix987","article-title":"A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1","volume":"66","author":"Huang","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1056\/NEJMoa1310422","article-title":"Single-dose oritavancin in the treatment of acute bacterial skin infections","volume":"370","author":"Corey","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-weekly dalbavancin versus daily conventional therapy for skin infection","volume":"370","author":"Boucher","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/jama.2013.241","article-title":"Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: The ESTABLISH-1 randomized trial","volume":"309","author":"Prokocimer","year":"2013","journal-title":"JAMA"},{"key":"ref_36","first-page":"4035148","article-title":"Measuring Surface Area of Skin Lesions with 2D and 3D Algorithms","volume":"2019","author":"Topfer","year":"2019","journal-title":"Int. J. Biomed. Imaging"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1128\/JCM.00044-16","article-title":"The Clinical Urine Culture: Enhanced Techniques Improve Detection of Clinically Relevant Microorganisms","volume":"54","author":"Price","year":"2016","journal-title":"J. Clin. Microbiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1473-3099(08)70228-7","article-title":"Pharmacodynamics and pharmacokinetics of antibacterial drugs in the management of febrile neutropenia","volume":"8","author":"Lortholary","year":"2008","journal-title":"Lancet Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Hung, S.K., Lan, H.M., Han, S.T., Wu, C.C., and Chen, K.F. (2020). Current Evidence and Limitation of Biomarkers for Detecting Sepsis and Systemic Infection. Biomedicines, 8.","DOI":"10.3390\/biomedicines8110494"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.biopha.2018.12.124","article-title":"Presepsin: A promising biomarker for the detection of bacterial infections","volume":"111","author":"Memar","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40560-017-0246-8","article-title":"Procalcitonin: A promising diagnostic marker for sepsis and antibiotic therapy","volume":"5","author":"Vijayan","year":"2017","journal-title":"J. Intensive Care"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1007\/s001340050715","article-title":"C-reactive protein as an indicator of sepsis","volume":"24","author":"Povoa","year":"1998","journal-title":"Intensive Care Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/978-1-0716-1488-4_16","article-title":"Sepsis Biomarkers","volume":"2321","author":"Kataria","year":"2021","journal-title":"Methods Mol. Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1164\/rccm.201408-1483OC","article-title":"Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial","volume":"190","author":"Shehabi","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_45","first-page":"1605","article-title":"Procalcitonin increase after endotoxin injection in normal subjects","volume":"79","author":"Dandona","year":"1994","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1093\/cid\/ciu732","article-title":"Use of procalcitonin in patients with various degrees of chronic kidney disease including renal replacement therapy","volume":"59","author":"Grace","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1515\/cclm-2020-0931","article-title":"Association of kidney function with effectiveness of procalcitonin-guided antibiotic treatment: A patient-level meta-analysis from randomized controlled trials","volume":"59","author":"Heilmann","year":"2020","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/cpt.2194","article-title":"Biomarker-Guided Individualization of Antibiotic Therapy","volume":"110","author":"Aulin","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_50","unstructured":"Centers for Disease Control and Prevention (CDC) (2021, September 28). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, [2017\u20132020], Available online: https:\/\/wwwn.cdc.gov\/nchs\/nhanes\/continuousnhanes\/default.aspx?Cycle=2017-2020."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1365-2710.2008.01016.x","article-title":"Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type","volume":"34","author":"Yamamoto","year":"2009","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/BF01061691","article-title":"Comparison of four basic models of indirect pharmacodynamic responses","volume":"21","author":"Dayneka","year":"1993","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"701480","DOI":"10.1155\/2015\/701480","article-title":"Procalcitonin levels in gram-positive, gram-negative, and fungal bloodstream infections","volume":"2015","author":"Leli","year":"2015","journal-title":"Dis. Markers"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/psp4.12015","article-title":"Establishing Good Practices for Exposure-Response Analysis of Clinical Endpoints in Drug Development","volume":"4","author":"Overgaard","year":"2015","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Marier, J.F., Jomphe, C., Peyret, T., and Wang, Y. (2021). Population pharmacokinetics and exposure-response analyses of teduglutide in adult and pediatric patients with short bowel syndrome. Clin. Transl. Sci.","DOI":"10.1111\/cts.13117"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e0179420","DOI":"10.1128\/AAC.01794-20","article-title":"Longitudinal Model-Based Biomarker Analysis of Exposure-Response Relationships in Adults with Pulmonary Tuberculosis","volume":"65","author":"Gewitz","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1111\/bcp.14523","article-title":"Pharmacologic effects of oseltamivir in immunocompromised adult patients as assessed by population PK\/PD analysis and drug-disease modelling for dosing regimen optimization","volume":"87","author":"Sturm","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40262-019-00820-x","article-title":"Population Pharmacokinetic and Exposure-Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease","volume":"59","author":"Snelder","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/cpt.2033","article-title":"Extrapolating Pharmacodynamic Effects from Adults to Pediatrics: A Case Study of Ustekinumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis","volume":"109","author":"Zhou","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1002\/jcph.1885","article-title":"Applying the Noninferiority Paradigm to Assess Exposure-Response Similarity and Dose Between Pediatric and Adult Patients","volume":"61","author":"Zhang","year":"2021","journal-title":"J. Clin. Pharmacol."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/11\/1368\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:27:51Z","timestamp":1760167671000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/11\/1368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,9]]},"references-count":60,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["antibiotics10111368"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics10111368","relation":{},"ISSN":["2079-6382"],"issn-type":[{"type":"electronic","value":"2079-6382"}],"subject":[],"published":{"date-parts":[[2021,11,9]]}}}